세계 올리고뉴클레오타이드 합성 시장 규모는 2024년 33억 달러에 달했습니다. 향후 IMARC Group은 2033년까지 시장 규모가 86억 달러에 달하고, 2025-2033년 10.55%의 연평균 성장률(CAGR)을 보일 것으로 예측했습니다. 대중들 사이에서 유전성 질환의 유병률 증가, 새로운 치료 전략의 개발, 저분자 간섭 RNA(siRNA) 및 항센스 올리고뉴클레오티드(antisense oligonucleotide)를 이용한 치료법의 보급이 시장을 주도하는 주요 요인 중 일부입니다.
올리고뉴클레오티드 합성이란 올리고뉴클레오티드라는 짧은 DNA 또는 RNA 분자를 미리 정해진 서열로 구성하는 과정을 말합니다. 올리고뉴클레오타이드의 길이는 몇 염기부터 약 200염기까지 다양합니다. 이 공정은 제어된 실험실 환경에서 화학적으로 이루어지며, 일반적으로 고체상 포스포아미드 화학을 사용합니다. 이 방법에서 뉴클레오티드는 성장하는 사슬에 순차적으로 첨가되며, 각각의 첨가는 일련의 화학반응을 동반합니다. 이 기술을 통해 과학자들은 유전자 합성, 중합효소 연쇄반응(PCR), CRISPR-Cas9와 같은 유전자 편집 도구, 분자진단 검사 등 다양한 용도의 맞춤형 올리고뉴클레오티드를 생성할 수 있습니다. 올리고뉴클레오타이드 합성의 발전은 유전체학 및 분자생물학 연구를 극적으로 가속화하여 의학 및 생물학 연구의 많은 돌파구를 마련했습니다.
대중들 사이에서 유전성 질환의 유병률이 증가하고 있는 것이 세계 시장을 크게 견인하고 있습니다. 따라서 올리고뉴클레오티드를 이용한 치료법이 중요한 역할을 하는 새로운 치료 전략의 개발이 요구되고 있습니다. 예를 들어, 저분자 간섭 RNA(siRNA)나 안티센스 올리고뉴클레오티드를 이용한 치료법은 뒤쉔형 근이영양증, 척수성 근위축증과 같은 유전성 질환의 치료에 연구 및 활용되고 있습니다. 이처럼 유전성 질환의 유병률 증가가 전 세계적인 수요를 견인하고 있습니다. 이와 함께 바이오인포매틱스와 데이터 사이언스의 성장이 올리고뉴클레오티드 합성 산업에 직접적인 영향을 미치고 있습니다. 대규모 유전체 데이터셋 분석 능력의 향상도 시장에 긍정적인 영향을 미치고 있습니다. 따라서 계산 능력의 향상은 신규 올리고뉴클레오타이드의 합성 수요 증가를 촉진하고 있습니다. 또한, 올리고뉴클레오타이드, 특히 안티센스 올리고뉴클레오타이드는 후성유전학 연구 및 치료에 효과적인 도구로 유전자 발현을 조절하는 데 도움이 되는 것으로 나타났습니다.
헬스케어 및 제약 산업 수요 증가
개인 맞춤형 의료 및 치료제에 대한 세계 수요가 빠르게 증가하면서 올리고뉴클레오타이드 합성 시장이 전례 없이 확대되고 있습니다. 이러한 합성 서열은 암을 포함한 다양한 유전성 질환 및 질병에 대한 표적 치료제를 개발하는데 필수적인 요소입니다. 이에 따라 안티센스 올리고뉴클레오티드, 앱타머, siRNA, 면역 자극성 올리고뉴클레오티드 등 치료용 올리고뉴클레오티드의 발전은 유전자 발현을 특이적으로 억제하거나 변화시킴으로써 질병 치료에 혁명을 일으키고 있습니다. 또한, 맞춤형 올리고뉴클레오타이드의 합성은 mRNA 기반 코로나19 백신을 포함한 백신 제조의 기본이며, 이는 효능이 입증되어 현재 널리 사용되고 있습니다. 제약회사와 연구자들이 질병 치료와 예방에 있어서 올리고뉴클레오타이드의 새로운 용도를 계속 발견함에 따라 올리고뉴클레오타이드 합성에 대한 수요는 계속 증가하고 있습니다.
기술 발전과 혁신
올리고뉴클레오타이드 합성 기술의 꾸준한 개발과 개선이 시장 개척의 원동력이 되고 있습니다. 또한, 하이스루풋 합성 시스템, 자동 합성 시스템 등 합성 공정의 기술 혁신으로 올리고뉴클레오티드 생산의 효율성, 정확성, 확장성을 향상시키고 있습니다. 또한, DNA 시퀀싱 및 유전자 편집(CRISPR-Cas9 등)을 포함한 바이오인포매틱스 및 합성생물학의 발전은 올리고뉴클레오티드를 정확하게 합성하는 능력에 크게 의존하고 있습니다. 이러한 발전은 더 복잡하고 다양한 맞춤형 서열을 생성할 수 있게 하고, 합성 생물학에서 신속한 프로토타입 테스트를 촉진하여 보다 효율적인 연구 개발을 촉진할 수 있게 합니다. 이러한 지속적인 기술 진보와 개발도 시장에 기여하고 있습니다.
공동연구 및 파트너십 확대
제약사, 생명공학 기업, 연구기관의 공동 연구와 파트너십은 유전성 질환에 대한 올리고뉴클레오티드 치료제의 개발 및 상용화에 있어 필수적인 원동력이 되고 있습니다. 이러한 협력 관계는 다양한 전문 지식, 자원, 자금을 결합하여 과학적 발견을 실용적이고 효과적인 치료법으로 가속화할 수 있는 시너지 환경을 조성하고 있습니다. 의약품 개발, 임상시험, 규제 프로세스 경험을 보유한 제약사는 공동연구에 필수적인 전문성을 제공합니다. 제약회사는 의약품 개발의 복잡한 상황을 극복하고 올리고뉴클레오티드 치료제가 안전성과 효능에 대한 규제 기준을 충족하도록 보장하는 데 필요한 인프라, 지식, 자원을 보유하고 있습니다. 그들의 참여는 기존 네트워크, 제조 능력, 유통 채널을 활용하여 상업화를 향한 여정을 간소화하는 데 도움이 될 것입니다.
The global oligonucleotide synthesis market size reached USD 3.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.6 Billion by 2033, exhibiting a growth rate (CAGR) of 10.55% during 2025-2033. The growing prevalence of genetic diseases among the masses, the development of novel therapeutic strategies, and the widespread adoption of therapies using small interfering RNAs (siRNAs), and antisense oligonucleotides are some of the major factors propelling the market.
Oligonucleotide synthesis refers to the process of constructing short DNA or RNA molecules, called oligonucleotides, in a predetermined sequence. These can range from just a few bases to around 200 nucleotides in length. The process is accomplished chemically in a controlled laboratory environment, typically using solid phase phosphoramidite chemistry. In this method, nucleotides are sequentially added to a growing chain, each addition involving a series of chemical reactions. This technology enables scientists to generate custom-made oligonucleotides for various applications including gene synthesis, polymerase chain reaction (PCR), gene editing tools, such as CRISPR-Cas9, and molecular diagnostic tests. Advances in oligonucleotide synthesis have dramatically accelerated research in genomics and molecular biology, underpinning many breakthroughs in medical and biological research.
The rising prevalence of genetic diseases among the masses majorly drives the global market. This necessitates the development of novel therapeutic strategies, where oligonucleotide-based therapies play a significant role. For instance, therapies using small interfering RNAs (siRNAs) and antisense oligonucleotides are being investigated and utilized in the treatment of genetic disorders, such as Duchenne muscular dystrophy and spinal muscular atrophy. As such, the growing prevalence of genetic diseases drives the demand on the global level. Along with this, the growth of bioinformatics and data science has a direct impact on the oligonucleotide synthesis industry. The escalating capacity to analyze large genomic datasets is also positively influencing the market. Therefore, the rising computational capability is driving an increased demand for the synthesis of novel oligonucleotides. Furthermore, oligonucleotides particularly antisense oligonucleotides, have been shown to be effective tools in epigenetic research and therapy, helping to modulate gene expression, which is creating a positive market outlook.
Rising Demand in the Healthcare and Pharmaceutical Industries
The global demand for personalized medicine and therapeutics is rapidly increasing, leading to an unprecedented expansion in the oligonucleotide synthesis market. These synthesized sequences are integral components in developing targeted therapies for various genetic disorders and diseases, including cancer. Along with this, the advancement of therapeutic oligonucleotides, such as antisense oligonucleotides, aptamers, siRNAs, and immunostimulatory oligonucleotides, is revolutionizing disease treatment by specifically inhibiting or altering gene expression. Furthermore, the synthesis of custom oligonucleotides is fundamental to the production of vaccines, including mRNA-based COVID-19 vaccines, which have proven effective and are now widely used. As pharmaceutical companies and researchers continue to discover novel applications for oligonucleotides in the treatment and prevention of diseases, the demand for oligonucleotide synthesis is poised to rise.
Technological Advancements and Innovation
The steady development and refinement of oligonucleotide synthesis technologies are driving market growth. In addition, innovations in the synthesis process, including high-throughput and automated synthesis systems, have increased the efficiency, accuracy, and scalability of oligonucleotide production. Moreover, developments in bioinformatics and synthetic biology, including DNA sequencing and gene editing (e.g., CRISPR-Cas9), heavily rely on the ability to synthesize oligonucleotides accurately. These advancements allow for the creation of custom sequences with greater complexity and diversity and facilitate rapid prototype testing in synthetic biology, thereby fostering more efficient research and development. These continuous technological advancements and developments are also contributing to the market.
Growing Collaborations and Partnerships
Collaborations and partnerships between pharmaceutical companies, biotechnology firms, and research institutions have become essential drivers in advancing the development and commercialization of oligonucleotide therapies for genetic diseases. These collaborations bring together diverse expertise, resources, and funding, creating a synergistic environment that accelerates the translation of scientific discoveries into practical and effective treatments. Pharmaceutical companies, with their experience in drug development, clinical trials, and regulatory processes, contribute vital expertise to the collaboration. They have the infrastructure, knowledge, and resources necessary to navigate the complex landscape of drug development and ensure that oligonucleotide therapies meet regulatory standards for safety and efficacy. Their involvement helps streamline the path to commercialization by leveraging existing networks, manufacturing capabilities, and distribution channels.
Synthesized oligonucleotide products dominate the market
The market for synthesized oligonucleotide products in the oligonucleotide synthesis industry is being driven by the ever-increasing demand from pharmaceutical and biotechnological companies for drug discovery and development, especially for personalized medicine and targeted therapeutics. Along with this, the rise in genomics and molecular research, fueled by significant advancements in technologies such as Next Generation Sequencing (NGS) and CRISPR gene-editing, is enhancing the requirement for synthesized oligonucleotides. Additionally, the growth in diagnostic applications of oligonucleotides, such as in PCR and microarray assays for genetic and infectious diseases, is propelling the market forward. The expanding field of epigenetics also represents a key driver, with oligonucleotides playing a crucial role in gene expression studies. Moreover, the increasing prevalence of genetic disorders and the resultant demand for novel therapeutic strategies involving oligonucleotides further accelerates the market growth for synthesized oligonucleotide products.
PCR primers dominate the market
The demand for PCR primers in the oligonucleotide synthesis industry is driven by the ongoing global health crisis necessitating extensive viral testing, in which PCR is a primary method. Furthermore, the increasing application of PCR in medical diagnostics, forensics, and research to detect genetic mutations and infectious diseases fuels the demand for primers. In the field of genomics and molecular biology, PCR is considered a crucial tool for DNA sequencing, cloning, and genetic manipulation, and this broad utilization further drives the need for PCR primer synthesis. Apart from this, technological advancements in PCR techniques, such as real-time PCR and digital PCR, are also playing a role in boosting demand. Moreoevr, the growing funding for research in healthcare and life sciences has resulted in expanded use of PCR, thus driving the demand for PCR primers in the overall industry.
Academic research institutes dominate the market
The demand for oligonucleotide synthesis in academic research institutes is driven by a rise in genomics and molecular biology research, particularly studies related to gene expression, genetic disorders, and the development of novel therapeutic strategies. Additionally, advancements in technologies such as Next-Generation Sequencing (NGS) and CRISPR gene-editing, which rely on synthesized oligonucleotides, are stimulating demand. In addition, the rising trend of interdisciplinary studies involving bioinformatics and data science, which necessitate the use of oligonucleotides for data validation, further drives the need. Governmental and institutional funding for genomics and biotechnology research is another major driver, enabling academic institutes to invest in oligonucleotide synthesis for various projects. Academic research institutes, with their focus on fundamental research and discovery, often possess cutting-edge knowledge and innovative ideas. By partnering with industry, they can translate their scientific findings into practical applications and commercial products.
North America exhibits a clear dominance, accounting for the largest oligonucleotide synthesis market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
The North American market for oligonucleotide synthesis is propelled by a robust pharmaceutical and biotech industry, with a strong focus on drug discovery and development. The region's emphasis on personalized medicine and targeted therapies further propels this need. Additionally, North America's sophisticated healthcare system with advanced diagnostic capabilities increases the demand for oligonucleotides in diagnostic assays. The region also hosts numerous top-tier academic and research institutes conducting extensive genomics and molecular biology research, which necessitates oligonucleotide synthesis. Moreover, strong governmental and private sector investment in healthcare and life sciences research, particularly in genomics and personalized medicine, fuels the growth of industry in North America. Moreover, the advancements in delivery systems and formulations for oligonucleotide-based therapeutics in North America demonstrate the region's commitment to pushing the boundaries of innovation in this field. These developments not only contribute to the growth of the market but also have the potential to revolutionize the treatment of various diseases, including genetic disorders, cancers, and rare diseases.
The global oligonucleotide synthesis market is experiencing significant growth due to the escalating investments in the development of new production facilities, upgrading existing ones, and implementing more efficient production processes. Therefore, Companies are heavily investing in research and development to innovate their offerings, including developing new synthesis techniques, improving the scale and accuracy of synthesis, and creating new types of oligonucleotide products to support various applications in diagnostics, therapeutics, and research. Along with this, companies are entering into strategic collaborations, partnerships, and acquisitions to co-develop oligonucleotide-based drugs, share technology and expertise, or expand into new markets. In addition, the introduction of therapeutics, such as antisense oligonucleotides, siRNAs, and miRNAs, offer new avenues for treating a wide range of diseases, including genetic disorders and cancers is positively influencing the market. Furthermore, key players are offering services for the custom synthesis of oligonucleotides. This allows researchers and developers to order specific oligonucleotide sequences tailored to their needs, which is particularly important in fields like genomics, molecular biology, and personalized medicine.